Menu

Experience

Richard Segal

    • SPAC BowX Agrees to Merger With WeWork 


    • Prelude – $182 Million IPO 


    • C4 Therapeutics – $210 Million IPO 


    • COMPASS Pathways – $147 Million IPO 


    • Inhibrx – $137 Million IPO 


    • ADC Therapeutics – $233 Million IPO 


    • iTeos Therapeutics – $201 Million IPO 


    • Inventiva – $108 Million IPO 


    • Akouos – $244 Million IPO 


    • Avidity Biosciences - $289 Million IPO 


    • Legend Biotech - $487 Million IPO 


    • Imara - $75 Million IPO 


    • Zentalis Pharmaceuticals - $190 Million IPO 


    • Schrodinger - $202 Million IPO 


    • Reata Pharmaceuticals – $505 Million Follow-On Offering 


    • argenx – $557 Million Follow-On Offering 


    • Innate Pharma - $79 Million IPO 


    • SpringWorks Therapeutics – $186 Million IPO  


    • Bellus Health – $70 Million IPO  


    • Karuna Therapeutics $103 million IPO 


    • Morphic Therapeutics - $104 Million IPO 


    • Akero Therapeutics - $106 Million IPO 


    • Bicycle Therapeutics - $61 Million IPO 


    • Stealth BioTherapeutics $78 Million IPO 


    • LogicBio Therapeutics – $80.5 Million IPO 


    • Endava – $146 Million IPO 


    • MeiraGTx – $75 Million IPO 


    • Cardlytics – $76 Million IPO 


    • Cooley Advises on Nightstar + NuCana IPOs 


    • Neon Therapeutics – $100 Million IPO 


    • Syros – $58 Million IPO 


    • Syros IPO – $58 Million 


    • Voyager Therapeutics - $80.5 Million IPO 


    • Rapid7 - $118 IPO 


    • Celyad Completes IPO 


    • DBV Technologies – $281.5 Million Follow-On Offering  


    • NetScout Systems to Acquire Danaher Communications Business for $2.6B 


    • Minerva – $58 Million Follow-On Offering 


    • AbCellera Biologics - $556 million IPO 


Contact us

Back to top

© 2021 Cooley LLP and Cooley (UK) LLP. All rights reserved.

Cooley® is a registered service mark of Cooley LLP in the United States and European Union as well as certain other jurisdictions.